Medication info

Sitak Em Tablet 50/1000 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
(Yoo) Hanpoong Pharmaceutical Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 120 tablets/bottle
Approval status
Active

MFDS item code 202201118 · Approved 2022.03.21

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience of diabetes drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Contraindications, section 2 of Precautions for Use). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When co-administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see General Precautions, section 5 of Precautions for Use). Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Ingredients

Manufacturer
(Yoo) Hanpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes. When taken with meal and exercise therapy, it can effectively manage blood sugar levels. The combination of sitagliptin and metformin enhances blood sugar control ability, helping to manage diabetes symptoms. Therefore, this drug improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience of diabetes drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily; this may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Contraindications, section 2 of Precautions for Use). 2. Patients treated with metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their existing doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When co-administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see General Precautions, section 5 of Precautions for Use). Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately.

Precautions

This medication contains two active ingredients, sitagliptin and metformin, and is primarily used for blood sugar control in patients with type 2 diabetes. First, this drug can cause allergic reactions, so if symptoms such as rash, urticaria, or difficulty breathing occur after administration, you should immediately stop taking it and consult a doctor. In addition, acute pancreatitis, a serious inflammation of the pancreas, may occur, so if symptoms such as abdominal pain, vomiting, or loss of appetite appear, you should immediately notify a medical institution. The metformin component can cause lactic acidosis, a rare but life-threatening metabolic complication; therefore, patients with impaired kidney function or liver dysfunction should not take this medication and should regularly undergo kidney function tests. This medication is not to be administered to patients with moderate or greater impairment of kidney function, acute heart failure, acute myocardial infarction, severe infection, or pregnant or nursing women. Additionally, the medication should be discontinued for a certain period before and after surgery, and caution is required when taken with other antidiabetic medications or alcohol as the risk of hypoglycemia may be increased. During the use of this medication, it is important to maintain a regular diet and exercise routine and regularly monitor blood sugar, kidney function, and vitamin B12 levels. If severe joint pain, skin blisters, itching, or difficulty breathing occur during treatment, you should immediately consult a physician. Lastly, the safety and effectiveness of this medication have not been established in children, and elderly patients should take it with extra caution due to the possibility of decreased kidney function.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 23 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesiculobullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • loss of appetite
  • weight loss
  • shortness of breath
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a dark place and kept in a tightly closed container at a temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 120 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.